Regeneron Pharmaceuticals (NASDAQ:REGN) PT Lowered to $1,050.00 at Wells Fargo & Company
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target decreased by Wells Fargo & Company from $1,200.00 to $1,050.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 9.11% […]
More Stories
The Best Food Scene You Don’t Know About Is in Buffalo, New York
By Adam Reiner, Bloomberg News Buffalo might be synonymous with hot wings, but there’s a less heralded bar staple that...
The Best Food Scene You Don’t Know About Is in Buffalo, New York
By Adam Reiner, Bloomberg News Buffalo might be synonymous with hot wings, but there’s a less heralded bar staple that...
Your Brain’s Secret Defense Against Alzheimer’s
By Brendon Fallon and Lynn Xu For many people, Alzheimer’s disease casts an increasingly large shadow as mental fog, forgotten...
Your Brain’s Secret Defense Against Alzheimer’s
By Brendon Fallon and Lynn Xu For many people, Alzheimer’s disease casts an increasingly large shadow as mental fog, forgotten...
Rivian Recalls Nearly 35,000 Delivery Vans Over Seat Belt Misuse Issue
By Rob Sabo Electric vehicle (EV) manufacturer Rivian Automotive announced on Dec. 3 it is recalling 34,824 delivery vans due...
Rivian Recalls Nearly 35,000 Delivery Vans Over Seat Belt Misuse Issue
By Rob Sabo Electric vehicle (EV) manufacturer Rivian Automotive announced on Dec. 3 it is recalling 34,824 delivery vans due...